Vertex to submit VX-445, Tezacaftor and Ivacaftor regimen for global regulatory approvals in cystic fibrosis

This article was originally published here

Final data announced today from a 24-week Phase 3 study in people with one F508del mutation and one minimal function mutation and from a 4-week Phase 3 study

The post Vertex to submit VX-445, Tezacaftor and Ivacaftor regimen for global regulatory approvals in cystic fibrosis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply